Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Celltrion
Incheon, South Korea
A
501-1000 Employees
2002
Key takeaway
Celltrion is a global biopharmaceutical company that offers comprehensive solutions for the entire biopharmaceutical process, from R&D to distribution. With its commitment to innovation and established biosimilars, Celltrion aims to enhance patient care and improve access to high-quality biologics.
Reference
Product
Technology
Femtobiomed
Seongnam-si, South Korea
A
11-50 Employees
2011
Key takeaway
FEMTOBIOMED.inc is focused on advancing targeted gene delivery through multiplexed cell therapeutics, highlighting their commitment to innovative approaches in cell therapy.
Reference
Core business
FEMTOBIOMED
GENECAST
Seoul, South Korea
A
11-50 Employees
2016
Key takeaway
GENECAST is a company that specializes in ctDNA liquid biopsy, which enhances cancer management by providing higher detection sensitivity and more treatment options. Their innovative ADPS™ technology significantly improves early detection in cancer diagnosis.
Reference
Core business
Liquid Biopsy for Cancer Diagnosis - GENECAST
GENECAST specializes in Liquid Biopsy for early detection in Cancer Diagnosis. We have developed ADPS™, a Technology with 0.001% sensitivity ✓ Contact Us.
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
BIORCHESTRA
Chungju-si, South Korea
A
1-10 Employees
2016
Key takeaway
BIORCHESTRA focuses on developing innovative RNA medicines and delivery systems addressing unmet medical needs, particularly in neurodegenerative and rare diseases of the Central Nervous System. Their best-in-class technology enhances the targeted delivery of RNA therapeutics, which may relate to advancing treatment approaches like CAR-T cell therapy.
Reference
Core business
BIORCHESTRA – Innovative RNA Therapeutics
Spidercore Inc.
Daejeon, South Korea
A
1-10 Employees
2020
Key takeaway
The company, Spidercore, focuses on enhancing gene therapy through its AI-driven platform that analyzes nucleotides' properties. Their innovative approach aims to improve clinical decision-making and patient outcomes in the promising field of gene-based therapies.
Reference
Core business
Spidercore Inc.
Medipost
Seongnam-si, South Korea
A
- Employees
-
Key takeaway
MEDIPOST has successfully commercialized CARTISTEM®, the world's first regulatory approved allogeneic stem cell product for treating degenerative osteoarthritis. This achievement highlights the company's leadership in stem cell therapeutics and its commitment to advancing regenerative medicine.
Reference
Service
Development Status - MEDIPOST
MEDIPOST stem cell treatment research and development status page. MEDIPOST succeeded in the commercialization of Cartistem, an allogeneic cord blood-derived mesenchymal stem cell treatment.
Onegene Biotechnology
Seongnam-si, South Korea
A
- Employees
2016
Key takeaway
Onegene Biotechnology is focused on advancing research and development, particularly in multi-target drug development. Their commitment to innovative therapies aligns with the growing interest in CAR-T cell therapy as a transformative approach in treating complex diseases.
Reference
Core business
ONEGENE BIOTECHNOLOGY
GC Genome
Yongin-si, South Korea
A
251-500 Employees
2013
Key takeaway
GC Genome Corporation offers a comprehensive portfolio that includes solutions for precision oncology and cancer panels, which are relevant to advancements in CAR-T cell therapy.
Reference
Core business
GC Genome | Clinical Genetic Testing | South Korea
GC Genome | Clinical Genetic Testing | NIPT | Newborn Screening | Cancer Panel | Precision Oncology | Health Checkup
Touchcare
Seongnam-si, South Korea
A
- Employees
-
Key takeaway
The company, DNX, focuses on enhancing the lives of seniors through innovative technologies like their Human Body Communication chip and AI persona, Suni, which promotes behavioral change and combats loneliness. Their partnership with Yonsei University Health System ensures that their services, which include remote care monitoring and data-driven interventions, are medically verified to improve mental health outcomes for the elderly.
Reference
Core business
Remote Care Monitoring | Touchcare
Loneliness abatement, data-driven behavioral change and remote care monitoring for the elderly and care-in-the-community populations
Cellgentek co. ltd.
Cheongju-si, South Korea
A
11-50 Employees
-
Key takeaway
Cellgentek specializes in developing advanced In Vivo Imaging Systems, which may be relevant for enhancing the understanding and monitoring of CAR-T cell therapy. Their focus on practical and cost-efficient bioimaging solutions could support research in this innovative treatment area.
Reference
Product
Bioimaing | Products | CELLGENTEK
ELLGENTEK is a company that conducts studies and invents to create the most optimal In Vivo Imaging System. CELLGENTEK aims at the practicality of bioimaging instrument and the cost-efficiency at the same time.
Technologies which have been searched by others and may be interesting for you:
When exploring the CAR-T cell therapy industry in South Korea, several key considerations emerge. The regulatory framework is vital, as the South Korean Ministry of Food and Drug Safety (MFDS) oversees the approval process for CAR-T therapies, ensuring compliance with safety and efficacy standards. This regulatory environment can influence the speed at which new therapies enter the market. Additionally, the competitive landscape is evolving, with both established pharmaceutical companies and innovative biotech startups actively participating, which can create both opportunities and challenges for new entrants. Researching the existing collaborations between academic institutions and industry players is crucial, as these partnerships often drive innovation and development in this field. Environmental concerns, particularly related to the bioengineering processes involved, are increasingly relevant, with growing emphasis on sustainable practices in biotechnology. Moreover, South Korea’s strategic position within the global market enhances the relevance of CAR-T therapies, as the country is recognized for its advanced healthcare system and significant investment in biotechnology. Finally, being aware of the challenges, such as high treatment costs and reimbursement issues, is essential for understanding the market dynamics and potential patient access to these therapies.
Some interesting numbers and facts about your company results for CAR-T Cell Therapy
| Country with most fitting companies | South Korea |
| Amount of fitting manufacturers | 17 |
| Amount of suitable service providers | 6 |
| Average amount of employees | 251-500 |
| Oldest suiting company | 2002 |
| Youngest suiting company | 2020 |
Some interesting questions that has been asked about the results you have just received for CAR-T Cell Therapy
What are related technologies to CAR-T Cell Therapy?
Based on our calculations related technologies to CAR-T Cell Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on CAR-T Cell Therapy?
The most represented industries which are working in CAR-T Cell Therapy are Biotechnology, Other, Medical, IT, Software and Services, Chemicals
How does ensun find these CAR-T Cell Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.